LoginRegister

    Shilpa Medicare gets USFDA nod for Irinotecan injection to treat cancer

    Farhat NasimWritten by Farhat Nasim   |  

    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.


    NEW DELHI: Shilpa MedicareTuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for the treatment of certain kind of cancers.


    The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single-dose vials, Shilpa Medicare said in a BSE filing.


    Also Read: Shilpa Medicare gets tentative USFDA nod for Dimethyl Fumarate delayed release capsules


    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.


    Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million.


    Also Read: Shilpa Medicare gets USFDA nod for Gemcitabine to treat types of cancer

    cancercancer drugcancer therapycancer treatmentcoloncolorectal cancerInjectionIQVIAirinotecanIrinotecan HCLirinotecan injectionmetastatic carcinomarectumShilpa MedicareUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X